Patheon — FY2011 Earnings Presentation
20 slides from Patheon's earnings presentation, Dec 19, 2011
Slide 1: Patheon Fiscal 2011 Results
December Exhibit 99.2 Patheon Fiscal 2011 Results
Slide 2: Forward-Looking Statements
This presentation contains forward-looking statements or information which reflect our expectations regarding possible events, conditions, our future growth, results of operations, performance, and business prospects and opportunities. All statements, other than statements of historical fact, are fo
Slide 3: Slide 3
Slide 4: Slide 4
Slide 5: Slide 5
Slide 6: Agenda
• 2011 Financial Results • Transformation Results • Q&A Agenda
Slide 7: Fiscal 2011 Results
Fiscal 2011 Results
Slide 8: Full Year 2011 Summary
Full Year 2011 Summary • Revenues for fiscal 2011 for Commercial Manufacturing were $572.6m up from $545.3m for fiscal 2010. Adjusted EBITDA for Commercial Manufacturing segment was $80.0m up from $72.3m for fiscal 2010. • Revenues for fiscal 2011 for Pharmaceutical Development Services were $127.4m
Slide 9: Select Financial Data
Select Financial Data This includes $32.9 M in 1Q11 and $17.5 M in 2Q11 related to deferred revenue and a reservation fee from an amended manufacturing supply agreement in the UK Quarterly results for fiscal 2011 Q1 2011 Q2 2011 Q3 2011 Q4 2011 (in millions of U.S. dollars) $ $ $ $ $ Revenues 175.7
Slide 10: Our strategy is executed across four elements
Our strategy will be executed across four elements Element I Strengthen core operations Element II Sell business differently Element III Enter adjacencies Element IV Drive industry consolidation Our strategy is executed across four elements
Slide 11: Strengthen our core operations
Operating System Mindsets, Capabilities & Behaviors Management Infrastructure The formal structures, processes and systems through which the operating system is managed to deliver the business objectives The way physical assets and resources are configured and optimized to create value and minimize
Slide 12: Strengthen our Core: Operational Effectiveness
2Q11 3Q11 4Q11 1Q12 2Q12 •Right First Time (Reduced Overtime) •Operational Flow Efficiencies & Output per Employee (ex. lab testing) •Improved Planning Process •Decreased Labor Costs •Increased Capacity (de- creased bottlenecks) •Increased throughput due to labor efficiencies •Develop Strategic Clie
Slide 13: Our strategy is executed across four elements
Element I Strengthen core operations Element II Sell business differently Element III Enter adjacencies Element IV Drive industry consolidation Our strategy is executed across four elements
Slide 14: CMO Market Trends and Implications
Source: PharmSource (2011) CMO Market Trends and Implications Competitive Landscape Trends • Highly fragmented market, and industry consolidation is progressing slowly • 3% to 5% annual growth forecasted (2011 – 2015) • CMOs continue to add capabilities/capacity despite indication of oversupply • Fr
Slide 15: PDS Market Trends and Implications
• Competition intensifies as new competitor types (e.g., CROs) have broadened their service offerings, expanding towards the PDS space • Reduced funding for emerging pharmas’ early development projects, and shrinking R&D efforts within big pharma, are forcing smaller CDOs to restructure/downsize • M
Slide 16: Lessons Learned: Sell business differently
Lessons Learned Biopharm Sell business differently Solution Based offerings that drive customer value Sterile Backup Supply SoluPath™ • Campaign messaging developed around solutions to our customers’ problems rather than our own existing capabilities • Fits a specific customer need which is currentl
Slide 17: Sell the business differently – early results
Sell the business differently – early results Sell the business differently – early results
Slide 18: Principles of our Strategy
Principles of our Strategy We will provide the industry’s leading customer experience. At all levels, places, and times our customers will have a predictably outstanding experience. Our factories must be the highest quality, most flexible, and most efficient producers in the world. Our Pharmaceutica
Slide 19: Q&A
Q&A
Slide 20: Appendix: Adjusted EBITDA Bridges
Appendix Adjusted EBITDA Bridges Q1 2011 Q2 2011 Q3 2011 Q4 2011 (in millions of U.S. dollars) $ $ $ $ $ Adjusted EBITDA 29.5 14.3 11.9 17.3 73.0 Depreciation and amortization (14.9) (13.5) (12.6) (12.4) (53.4) Repositioning expenses (0.9) (0.7) (1.9) (3.5) (7.0) Interest expense, net (6.3) (6.3) (6